Search Results
Mar 31, 2026, 20:49 ET The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
demonstrating that manufactured biologics can deliver sustained, measurable reversal of chronic organ damage.Iovance Biotherapeutics (NASDAQ: IOVA) received FDA approval for Amtagvi, a tumor-infiltrating lymphocyte therapy for advanced melanoma — the first approved TIL therapy, which requires extracting
More news about: USA News Group
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
demonstrating that biological interventions can deliver sustained, measurable reversal of chronic organ damage.Iovance Biotherapeutics (NASDAQ: IOVA) received FDA approval for Amtagvi, the first approved tumor-infiltrating lymphocyte therapy for advanced melanoma. It's a landmark, but each treatment
More news about: USA News Group
Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
multiple tumor types include Oncolytics Biotech (NASDAQ: ONCY), Vir Biotechnology (NASDAQ: VIR), Iovance Biotherapeutics (NASDAQ: IOVA), C4 Therapeutics (NASDAQ: CCCC), and Immunocore (NASDAQ: IMCR).
More news about: Equity Insider
Oct 29, 2025, 08:30 ET Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
as an innovator along with other companies working to make a difference in cancer treatment, including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ)
More news about: NetworkNewsWire
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Therapeutics, Inc. (NASDAQ: PSTV), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), and I-Mab (NASDAQ: IMAB).
More news about: Equity Insider
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
cancer and rare diseases are treated. In doing so, it positions itself among the innovators — including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Bristol-Myers Squibb Co. (NYSE: BMY) — that are driving advances
More news about: NetworkNewsWire